Neuphoria Therapeutics Inc. Overview
Pro stress-test →Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024.
Strategic Profile
Pro stress-test →Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions.
Competitive Landscape
Pro stress-test →Neuphoria competes in the CNS therapeutics space against larger pharma developing anxiety and psychiatric disorder treatments. The company's focus on ion channel modulators for neuropsychiatric indications positions it in a specialized market segment with competitors pursuing similar or adjacent mechanisms.
Industry Context
Neuphoria Therapeutics Inc. operates in Biopharmaceutical / Clinical-Stage Drug Development.
Key facts
Founded: 1996 · Headquarters: Burlington, Massachusetts · Market cap: $23.4M